Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion. 1990

M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
Department of Hemodialysis, Tadaoka Municipal Hospital, Osaka, Japan.

Red blood cell (RBC) aluminum (Al) in patients with renal failure on different treatments was studied. Nondialyzed renal failure patients had high levels of RBC Al, but low serum Al levels. However, their RBC Al levels were lower than those of patients on hemodialysis (HD) and continuous ambulatory peritoneal dialysis. In addition, HD patients who were not given Al-containing medications showed high levels of RBC Al, which suggests that there may be a source of Al other than medications. When desferrioxamine (DFO) was administered to these HD patients, the changes in RBC Al levels after DFO infusion were independent of those in serum Al levels and blood hemoglobin levels. In an in vitro study, RBC Al was removed using an ultrafiltration membrane, which showed that RBC Al exists in a bound form. These results suggest that Al accumulates in RBCs of renal failure patients independently of serum Al levels, and that the improvement of anemia by DFO may not be due to the direct removal of RBC Al.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000535 Aluminum A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98. Aluminium,Aluminium-27,Aluminum-27,Aluminium 27,Aluminum 27

Related Publications

M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
June 1988, Journal of trace elements and electrolytes in health and disease,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
August 1987, Wiener medizinische Wochenschrift (1946),
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
January 1982, Nephron,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
January 1984, Transactions - American Society for Artificial Internal Organs,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
January 1987, Nephron,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
January 1997, Acta biochimica Polonica,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
October 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
June 1984, Research communications in chemical pathology and pharmacology,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
January 1982, Transplantation,
M Umeda, and K Tsurusaki, and S Kamikawa, and N Izumi, and R Yasumoto, and T Kishimoto, and M Maekawa
December 1993, Therapeutic drug monitoring,
Copied contents to your clipboard!